rituximab,ocrelizumab,ublituximab,ofatumumab,teriflunomide
i-mab,biogen,roche,tg therapeutics,novartis
['ritux', 'ocrelizumab', 'ublituximab', 'ofatumumab', 'imab ', '$rhhby', '$tgtx']
ectrims2022:
all anti-cd20 monoclonal antibodies have similar efficacy and safety risks: yes #ofatumumab #rituximab #ocrelizumab #ublituximab $tgtx $rhhby #ectrims22 #ectrims2022
Master of Disaster ;-)